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Abstract: Levosimendan was first approved for clinical use in 2000,
when authorization was granted by Swedish regulatory authorities for
the hemodynamic stabilization of patients with acutely decompensated
chronic heart failure (HF). In the ensuing 20 years, this distinctive
inodilator, which enhances cardiac contractility through calcium
sensitization and promotes vasodilatation through the opening of
adenosine triphosphate–dependent potassium channels on vascular
smooth muscle cells, has been approved in more than 60 jurisdictions,
including most of the countries of the European Union and Latin
America. Areas of clinical application have expanded considerably and
now include cardiogenic shock, takotsubo cardiomyopathy, advanced
HF, right ventricular failure, pulmonary hypertension, cardiac surgery,
critical care, and emergency medicine. Levosimendan is currently in
active clinical evaluation in the United States. Levosimendan in IV
formulation is being used as a research tool in the exploration of a wide
range of cardiac and noncardiac disease states. A levosimendan oral
form is at present under evaluation in the management of amyotrophic
lateral sclerosis. To mark the 20 years since the advent of levosimendan
in clinical use, 51 experts from 23 European countries (Austria,
Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France,
Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland,
Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United
Kingdom, and Ukraine) contributed to this essay, which evaluates one
of the relatively few drugs to have been successfully introduced into the
acute HF arena in recent times and charts a possible development tra-
jectory for the next 20 years.
Key Words: acute heart failure, advanced heart failure, hemody-
namics, inodilator, inotrope, neurohormone, regulatory clinical trial
(J Cardiovasc Pharmacol 2020;76:4–22)
ORIGINS OF A UNIQUE
CARDIOVASCULAR AGENT
Before the 1980s, therapy to enhance cardiac contractility
in heart failure (HF) substantially meant oral digitalis glycosides,
supplemented by beta-adrenergic agonists such as dopamine or
dobutamine (introduced in the middle of the 1970s) in acute
situations.1 It was therefore a matter of some note when the US
Food and Drug Administration approved a new agent as a short-
term IV therapy for patients with refractory HF. Amrinone was
the product of a widespread research initiative that recognized the
limitations of existing inotropic therapy and that, equipped with
a new understanding of the cellular mechanisms of cardiac con-
tractility, set out to develop what respected commentators of the
time referred to as “non-glycoside, non-sympathomimetic posi-
tive inotropic agents.”2–4 Amrinone was the first agent to reach
clinical use from the small but important family of phosphodi-
esterase (PDE) inhibitors, which would later include milrinone
and enoximone.5,6 However, despite being nonsympathomi-
metic positive inotropic agents, all PDE inhibitors, in common
with the catecholamines, were shown to be calcium mobilizers,
probably due to their limited selectivity toward specific key
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PDE isoforms, and shared with catecholamines some unwanted
effects intrinsic to any drug that raises intracellular calcium. In
fact, all calcium mobilizers, by definition, exert an inotropic
effect by providing increased ionic calcium levels for the con-
tractile protein machinery, a process that may ultimately prove
detrimental to individual cardiomyocytes and therefore also to
patients.7
At about the same time, a new concept was proposed by
the independent groups of J Caspar Rüegg in Heidelberg and
R. John Solaro in Chicago, namely the potential of new
agents to enhance the sensitivity to calcium of key targets
in the contractile apparatus instead of increasing the intracel-
lular calcium transient to augment contractility.8,9 In 1984,
Rüegg et al10 described the pharmacology of a new agent,
later known as pimobendan, which combined PDE inhibitor
activity with a direct calcium-sensitizing effect.
It was in this climate of innovation that the new
chemical entity R-((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-
pyridazinyl)phenyl)hydrazono)propanedinitrile, known by
the identifier OR-1259 at the time, appeared in the published
records. An abstract was published in 1992 describing “a
positive inotropic and vasodilatory compound with antiar-
rhythmic properties.”11 This preliminary report noted
that OR-1259 exerted a positive inotropic effect despite
a reduction in the voltage-sensitive Ca2+ current. As is not
uncommon in abstract reports, the authors advised that
“Further studies. are in progress.”
In 1995, Heimo Haikala reported the findings of in-
depth research into the mechanism of action of this agent in
his pioneering paper.12 At the same time, an article describing
the binding of a new Ca2+ sensitizer, levosimendan, to re-
combinant human cardiac troponin C was also published.13
Those first descriptions may be regarded as foundation pub-
lications in the chronology of this drug and a starting point for
the PubMed-cited literature on levosimendan, which had
expanded to almost 1500 reports by the end of 2019.
Levosimendan was described as “a calcium sensitiser ratio-
nally designed and screened to act through its calcium-dependent
binding to cardiac troponin C,” and the experimental basis for
this description was set out in detail.12 From the beginning, clear
mechanistic differences were spotted between levosimendan and
several other drugs then in development, including pimobendan,
MCI-154, and EMD 53998. Levosimendan was a first-in-class
agent at the time of its emergence, promoting inotropy mainly
through calcium sensitization of cardiac troponin C (cTnC).
More than 20 years later it remains, remarkably, an only-in-
class drug, with a mechanism of action that clearly differentiates
it from adrenergic agents.
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Levosimendan, as reported by Pollesello et al13 in 1994,
binds to calcium-saturated human cTnC “in a hydrophobic
patch of the N-domain near the site where the B helix is
located when the protein is in its apoform.” Figure 1 shows
an original diagram from the 1994 paper proposing a molec-
ular model of the drug–ligand complex.
That interaction leads to a stabilization of the calcium-
bound conformation of the regulatory (or N) domain of cTnC,
which in turn causes a change in the conformation of the
‘switch’ region of cardiac troponin I (cTnI) and detachment of
cTnI from actin filaments.14 Removal of the inhibitory effects
of cTnI facilitates the formation of actin–myosin cross-bridges
and the disinhibition of actomyosin adenosine triphosphate
(ATP) synthase, resulting in enhanced cardiac contractil-
ity.12,13,15–18 These findings, confirming that the binding of
levosimendan to TnC is linked to calcium sensitization, proved
to be the first stage of what has since matured into a long-
lasting research trail.19–22
The calcium-sensitizing action of levosimendan is
manifested as a leftward shift in the curve describing the
relation between contractile force and calcium concentration,
achieved through a direct effect on cTnC. That augmentation
of contractility is not associated with increases in calcium
transients, intracellular calcium, or myocardial oxygen con-
sumption and is not compromised by pretreatment with beta-
blockers. It should also be noted that the interaction between
levosimendan and cTnC was shown to be more intense at
high, systolic ionic calcium levels than at low, diastolic
calcium levels, thus avoiding impairment of myocardial
relaxation upon levosimendan administration.
In addition to its principal action as a calcium-sensitizing
agent, levosimendan was found in the course of its development
program to mediate the opening of ATP-dependent potassium
channels (KATP channels) in vascular smooth muscle cells in
various vascular beds.23 By this mechanism of action, levosi-
mendan induces an increase in blood perfusion in key organs
and a systemic vasodilatation when levosimendan is used at
doses within the recognized therapeutic range, which means that
the drug must be considered and used as an inodilator and not
simply as an inotrope. An essential aspect of the pharmacology
and clinical profile of levosimendan is that its perfusion
enhancement and systemic vasodilation effects are mediated
through different mechanisms and may therefore be disentangled
from each other. Levosimendan—acting on KATP channels—
has a different regional/peripheral versus systemic effect when
compared with drugs such as the PDE inhibitors.24
Separate emphasis must be placed on the discovery that
levosimendan also opens the KATP channels on the mitochon-
drial inner membrane.25,26 This effect has been associated with
cardioprotection, infarct size reduction, and mitigation of
ischemia/reperfusion injuries in a range of in vitro, ex vivo,
and in vivo studies in nonhuman species27–31 and in clinical
studies.32
The aforementioned effects deriving from calcium sensi-
tization and vasodilation are shared by the long-acting levosi-
mendan metabolite OR-1896, which is formed in the intestine
through a reduction–acetylation pathway.33–35 Free plasma con-
centrations of the parent drug and the metabolite are similar, but
clinically meaningful plasma concentrations of pharmacologi-
cally active OR-1896 are detectable for days after an infusion of
levosimendan and contribute to the persistence of the therapeutic
effect after administration of the parent drug is stopped.36
Beyond these primary mechanisms, levosimendan has
been identified as having a range of ancillary actions (often
described as pleiotropic effects) that do not involve an
enhancement of cardiac function but which may be implicated
in some of the clinical effects of and responses to levosi-
mendan.37 These include anti-inflammatory, antioxidative,
and antiapoptotic actions that may be exerted in noncardiac
organs, including the kidneys, liver, gut and splanchnic vas-
culature, lungs, and/or respiratory muscles (Fig. 2).
Levosimendan inhibits only one isoform of intracellular
PDE enzymes (PDE-III) and in a highly selective manner. Of
note, the PDE-III over PDE-IV isoform selectivity of levosi-
mendan is the highest known to date, with a ratio of 10,000,
FIGURE 1. Early molecular model of the levosimendan–cTnC
complex: The dihydropyridazinone ring of levosimendan is
enclosed within a hydrophobic cleft formed by the amino acid
residues Phe20, Ala22, Ala23, Phe24, Val28, and Phe77, and the
phenyl ring of levosimendan is aligned to Met81, Cys84, and
Met85. Source: Pollesello et al13 Reproduced with permission
from the American Society for Biochemistry and Molecular
Biology. cTnC = cardiac troponin C.
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compared with 14 for milrinone.38,39 It was proposed that inhi-
bition of only the PDE-III isoform, not that of PDE-IV, would
be insufficient to increase intracellular levels of cyclic adenosine
monophosphate (cAMP) to the same levels as by simultaneous
inhibition of the 2 isozymes.38 This lack of PDE dependence
further differentiates levosimendan from nonselective PDE in-
hibitors, such as milrinone, and provides an explanation of their
different pharmacological behaviors, as in the case of the oxygen
consumption to force production ratios.38,40–42
However, this interpretation is not unanimous. Maack
et al43 have proposed that PDE-III inhibition by levosimendan
may indeed play a relevant role in the pharmacological effects
of levosimendan. In that interpretation, PDE-III inhibition by
levosimendan synergizes with Ca2+ sensitization for the result-
ing inotropic action. Interestingly, from this synergy, the au-
thors predict that the more beta-adrenergic receptors are
preactivated by endogenous or exogenous catecholamines,
the more pronounced will be the inotropic effect of levosimen-
dan, and the more this effect would be mediated by PDE-III
inhibition rather than by Ca2+ sensitization. Conversely, at low
preactivation of beta-adrenergic receptors (such as during phar-
macological beta-blockade), the Ca2+-sensitization effect of
levosimendan would become more important for inotropy.
The take-home message of a consensus paper from the
Translational Working Group of the Heart Failure
Association of the European Society of Cardiology (ESC) is
that long-term use of drugs that exclusively target adrenergic
signaling (eg, catecholamines and PDE inhibitors) is associated
with adverse outcomes, whereas levosimendan, with its hybrid
calcium sensitization and PDE-III inhibition properties, should
be given the benefit of the doubt and further attention.
The effect of levosimendan has also been studied in the
presence of beta-blockers and/or inopressors. Xanthos et al44
reported that the combination of epinephrine, atenolol, and lev-
osimendan, when given during cardiac arrest and resuscitation in
a pig model, resulted in improved 48-hour survival and postre-
suscitation cardiac function. Concurrently, Lochner et al45 re-
ported that the effects of levosimendan were not blunted by the
presence of beta-blockers, as in the case of adrenergic inotropes.
Levosimendan entered formal clinical evaluation and
development in acute HF (AHF) in the mid-1990s.46–48
Initially, it was established that IV levosimendan produced
dose-dependent increases in cardiac output (CO) and decreases
in pulmonary capillary wedge pressure (PCWP; Fig. 3). Those
effects were not accompanied by significant increases in myo-
cardial energy consumption, thus confirming the paradigm en-
visioned on the basis of the preclinical data.28,49–51
FROM BENCH TO BEDSIDE
Levosimendan entered clinical trials profiled as a novel
inotrope with potential for the short-term treatment of acutely
decompensated chronic HF. The regulatory studies program
devised to evaluate it in this indication enrolled almost 4000
patients (Table 1) and produced the following key insights.
Clinical Effects
Hemodynamic Effects
The hemodynamic effects of levosimendan seen in
preclinical studies were confirmed. In patients with AHF,
levosimendan achieves significant dose-dependent increases
FIGURE 2. Mode of actions and pharmacologic effects of levosimendan: The mechanisms of action in the blue boxes contribute
to the cardiovascular effects of the drug. Dotted lines mark pathways that are still not fully elucidated. EC50, half maximal effective
concentration; KATP, adenosine triphosphate–dependent potassium channels; PDE III, IV, phosphodiesterase isoforms in cardiac
tissue. Adapted from: Al-Chalabi et al216 Used with permission from Wolters Kluwer Health.
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in CO and stroke volume and decreases in PCWP, mean
blood pressure, mean pulmonary artery pressure, mean right
atrial pressure, and total peripheral resistance.52
In line with preclinical data, clinical studies have
confirmed that levosimendan does not have a negative effect
on diastolic function. In contrast, levosimendan has lusitropic
FIGURE 3. Change in CO and PCWP: Change
from baseline at the conclusion of a 24-hour
infusion of levosimendan (given as a 10-minute
bolus of 6–24 mg/kg, then an infusion of 0.05–
0.6 mg/kg/min), placebo, or dobutamine
(6 mg/kg/min) in patients with stable HF. DOB,
dobutamine; PBO, placebo. Data from:
Nieminen et al.52
TABLE 1. Regulatory Clinical Trials of Levosimendan
Study
n (Total/
LS)
Dose (mg/kg/min)/Duration of
LS Infusion Comparator
Diagnosis/NYHA
Class Primary Endpoint
Dose ranging52 151/95 0.05–0.6
24 h
Placebo/
dobutamine
CHF/III Invasive
hemodynamics
Dose escalation and
withdrawal64
146/98 0.1–0.4
24 or 48 h
Placebo CHF/III–IV Invasive
hemodynamics
LIDO63 203/103 0.1–0.2
24 h
Dobutamine CHF/III–IV Invasive
hemodynamics
RUSSLAN65 504/402 0.1–0.4
6 h
Placebo Post-AMI/IV Safety
REVIVE I62 100/51 0.1–0.2
24 h
Placebo CHF/IV Clinical composite
REVIVE II62 600/299 0.1–0.2
24 h
Placebo CHF/IV Clinical composite
SURVIVE61 1327/664 0.1–0.2
24 h
Dobutamine CHF/IV Mortality
AMI, acute MI; CHF, congestive heart failure; LS, levosimendan; NYHA, New York Heart Association.
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effects.53,54 Inodilation is not only seen in the left side of the
heart; right ventricular contractility is also improved, and
pulmonary vascular resistance is decreased.55–57
Pharmacokinetics in Clinical Trials
As anticipated in nonclinical studies, in humans the
hemodynamic effects of a 24-hour infusion of levosimendan
are protracted for several days in patients with AHF due to of
the presence of an active metabolite (Fig. 4A).58–60
Effects on Neurohormones
Rapid and sustained reductions in levels of natriuretic
peptides were characteristic of levosimendan in its regulatory
clinical trials.61–63 The effect on natriuretic peptides closely
follows the hemodynamic effects: both are evident for at least
1 week after the levosimendan infusion period (Fig. 4B).58 In
the trial Survival of Patients with Acute Heart Failure in Need
of IV Inotropic Support (SURVIVE), in patients with acute
decompensated HF, changes in brain natriuretic peptide
(BNP) levels up to 5 days after the start of infusion of levo-
simendan could be seen, which was not the case after 48 hours
of treatment with dobutamine.61
Impact on Signs and Symptoms in AHF
Levosimendan induces a rapid and sustained improve-
ment in symptoms, as evidenced by Packer et al62 and
Slawsky et al.64 In the second of those studies, relief of dysp-
nea was reported in 29% of levosimendan-treated patients
compared with 15% of the placebo-treated patients 6 hours
after starting the infusion (P = 0.037).64 Improvement in
symptoms was evident for up to 5 days.62 Data on the use
of rescue medications in the Randomised Evaluation of IV
FIGURE 4. Pharmacokinetics of levosimendan: A,
Differences in the area under the receiver oper-
ating characteristics curve (AUC) for changes in
Doppler echocardiography–derived PCWP and
CO in patients with acute HF treated with levo-
simendan or placebo (n = 11 in both groups) for
24 hours. Due to of the formation of the active
metabolite, the hemodynamic effects are main-
tained several days after stopping levosimendan
infusion. B, Median change in N-terminal pro-
hormone atrial natriuretic peptide (NT-proANP)
over 14 days in patients with HF receiving levo-
simendan or placebo (n = 11 in both groups) for
24 hours. Source: Lilleberg et al58 Reproduced
with permission from John Wiley and Sons.
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Levosimendan Efficacy (REVIVE) program further confirm
the effectiveness of levosimendan for symptom relief
(Table 2).62 Dyspnea and fatigue symptoms also responded
better to levosimendan than to dobutamine in the
Levosimendan Infusion versus Dobutamine (LIDO) trial,
although not to the level required for statistical significance.63
Clinical Outcomes
Hospitalizations
Patients treated with levosimendan in the LIDO study
spent significantly more days alive and out of hospital than
dobutamine-treated patients in a retrospective 180-day
follow-up analysis (median 157 vs. 133 days; P = 0.027).63
In the Randomised Study on Safety and Effectiveness of
Levosimendan in Patients with Left Ventricular Failure
After an Acute Myocardial Infarction (RUSSLAN), the com-
bined risk of death and worsening HF was significantly lower
in patients treated with levosimendan than in the control
group during the infusion period (2% vs. 6%; P = 0.033)
and at 24 hours (4% vs. 9%; P = 0.044).65 In the REVIVE
II study, a greater percentage of patients treated with levosi-
mendan than placebo were released within 5 days (46% vs.
37%), and the mean duration of the initial hospitalization was
almost 2 days shorter (7.0 vs. 8.9 days).62 No significant
intergroup difference was recorded in the SURVIVE trial (P
= 0.3).61
Mortality
Thirty-one-day mortality in the LIDO trial indicated
a survival advantage from levosimendan (mortality rate 8%,
vs. 17% with dobutamine, HR 0.43, P = 0.049).63 This was
corroborated in a retrospective extension of follow-up to 180
days (mortality rate 26%, vs. 38% with dobutamine, HR 0.57,
P = 0.029). In RUSSLAN, a survival benefit from levosimen-
dan persisted at 180-day follow-up (23% vs. 31%; P =
0.053).65
In the REVIVE and SURVIVE trials there were no
significant differences in 3- and 6-month overall survival
between the study groups.61,62 However, there was evidence
of a survival gain from levosimendan treatment in SURVIVE
patients who had a history of chronic decompensated HF or
who were using beta-blockers.66 In patients with existing
chronic HF (88% of the study population), mortality was
lower in the levosimendan group than in the dobutamine
group at day 5 [3.4% vs. 5.8%, HR 0.58, 95% confidence
interval (CI) (0.33–1.01), P = 0.05] and at day 14 [7.0% vs.
10.3%, HR 0.67, 95% CI (0.45–0.99), P = 0.045]. In patients
who used beta-blockers (50% of the study population),
mortality was significantly lower for levosimendan than for
dobutamine at day 5 [1.5% vs. 5.1%, HR 0.29, 95% CI (0.11–
0.78), P = 0.01].
Safety
A safety summary prepared by Orion Pharma in its
capacity as sponsor of the regulatory studies found no
difference in the proportion of patients with reduction in
arterial blood pressure in response to treatment (23.1% vs.
23.1%), although REVIVE II, considered as a single study,
diverged from this overall trend by showing more hypoten-
sion in the levosimendan arm.62 In 2012, Landoni et al67
collected data from 5480 patients in 45 randomized clinical
trials and also carried out meta-analysis of the adverse events.
No signals were seen for MI [data from 25 studies, RR 0.789,
95% CI (0.522–1.185), P = 0.3], ventricular arrhythmias [data
from 9 studies, RR 0.885, 95% CI (0.611–1.281), P = 0.5], or
supraventricular arrhythmias [data from 19 studies, RR 1.005,
95% CI (0.782–1.291), P = 0.9], but a numerical trend was
seen for hypotension [data from 22 studies, RR 1.389, 95%
CI (0.996–1.936), P = 0.53]. There are some contradictory or
indirect and inconclusive reports related to the impact of
levosimendan on platelet function, but a recent meta-
analysis of 9 randomized controlled trials (RCTs) found that
levosimendan did not increase postoperative bleeding
risk.68,69 Moreover, in Supplemental Digital Content 1
(see Supplementary Appendix, http://links.lww.com/JCVP/
A472) of the large regulatory trial Levosimendan in Patients
with Left Ventricular Systolic Dysfunction Undergoing
Cardiac Surgery Requiring Cardiopulmonary Bypass
(LEVO-CTS) no signs of increase in periprocedural or post-
procedural hemorrhage were seen after treatment with
levosimendan.70
Conversely, a later, independent meta-analysis of data
from more than 5000 patients indicated increased risks of
extrasystoles [RR 1.88, 95% CI (1.26–2.81)], hypotension [RR
1.33, 95% CI (1.15–1.53)], and headache or migraine [RR 1.94,
95% CI (1.54–2.43)] when compared with reference therapies.71
Retrospective analyses of the REVIVE II data set identified low
TABLE 2. Use of Rescue Medications in the REVIVE Program
REVIVE I62 REVIVE II62
Levosimendan (n = 51) Placebo (n = 49) Levosimendan (n = 299) Placebo (n = 301)
Rescue therapy (%) 16 29 15 26
Worsening dyspnea or tachypnea (%) 10 12 7 13
Increased pulmonary edema (%) 0 2 3 6
Diaphoresis (%) 0 2 1 1
Cool extremities and cyanosis (%) 2 2 0 2
Worsening renal function (%) 6 2 3 5
Decreased mental status (%) 0 0 1 2
Persistent/unresponsive
symptoms (%)
10 18 6 11
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blood pressure at baseline as a possible risk factor for the use of
levosimendan, and the current, approved Summary of Product
Characteristics reflects that finding.72
Dosing
Levosimendan is given as a continuous infusion of 0.05
or 0.1 or 0.2 mg/kg/min for 24 hours, which may be preceded
by a loading dose (bolus) of 6–12 mg/kg in 10 minutes. The
loading dose was used in the active-controlled regulatory
studies LIDO and SURVIVE, in which dobutamine served
as comparator. Given that the elimination half-life of dobut-
amine is a few minutes while that of levosimendan is approx-
imately 1 hour, the hemodynamic effects of dobutamine are
seen almost immediately after the infusion is started, whereas
a bolus of levosimendan is needed to see immediate effects.
For consistency, all other studies in the regulatory clinical
program were designed to include a bolus dose, followed
by a maintenance infusion. It was later found that, in the case
of hypovolemia or initial low blood pressure, a levosimendan
bolus could be associated with hypotension or arrhythmias.
Therefore, use of an initial bolus of levosimendan is now
generally not recommended, and it has often been avoided
in clinical practice and used only if an instant effect is sought
and the systolic blood pressure is adequate.73,74
Into Regular Clinical Use
The experience gained in regulatory studies provided
the basis for the first approval of IV levosimendan, which was
introduced in Sweden in 2000 for the management of AHF
with the name SIMDAX. Since then, more than 60 juris-
dictions have approved the drug, including most of the
countries of the EU and Latin America. Levosimendan is
currently in active clinical evaluation in the United States.
In the 20 years since its first introduction, IV levosi-
mendan has been one of the notably few successful drugs
entering the market in an underserved area of cardiovascular
medicine: attempts at drug innovation in AHF have been
characterized by repeated disappointments (either partial or
total) or contradictory findings that have hindered progress.75
Levosimendan itself has not been immune to some of
the frustrations of research in this area: in particular, the
nonunivocal findings on 6-month mortality in its regulatory
studies complicated the process of establishing its therapeutic
niche. Innovation in this area may have been poorly served by
a regulatory emphasis on longer-term survival effects. This
was perhaps misaligned with clinical realities and led to an
emphasis on large trials which, by aggregating data from
patients with different underlying pathophysiologies plus
variations in both pharmacological and nonpharmacological
treatments, may have generated signal-to-noise ratios that
precluded the identification of a meaningful effect on the
central end point of all-cause mortality/survival. The unsuit-
ability of all-cause long-term mortality as an index of
therapeutic effect was acknowledged by experts in the field
of HF about a decade ago, but that realization came too late to
influence the conduct of the regulatory trials of
levosimendan.76,77
These obstacles notwithstanding, pooled analysis of the
outcomes of the levosimendan regulatory trials provided
strong indications, albeit not always statistically conclusive
proof, of an overall survival benefit (Fig. 5). Extensive expe-
rience with levosimendan has been accrued in smaller, often
single-center, nonregulatory studies. Many of those studies
indicate a survival benefit from levosimendan, a finding af-
firmed in meta-analysis.67
Levosimendan has been evaluated in more than 200
clinical trials during its lifetime, in an extensive range of
therapeutic settings. Experience in all those areas has been
evaluated in meta-analyses, 31 of which have been conducted
in the past 3 years (Fig. 6). In every instance, levosimendan
FIGURE 5. Effect of levosimendan
on survival in the regulatory clinical
trials: Meta-analysis of the clinical
trials considered by regulatory
authorities for the introduction of
levosimendan. *Pooled statistic cal-
culated using the Cochran–Mantel–
Haenszel test, controlling for study.
Source: Pollesello et al.80
Reproduced with permission from
Elsevier.
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was associated with a favorable impact on the outcomes
under consideration but, depending on the data selected, sta-
tistical significance in some cases remained elusive. Key ther-
apeutic areas analyzed in this way have included AHF,
advanced HF (AdHF), cardiac surgery, and sepsis, all of
which have provided indications of benefit from levosimen-
dan therapy.
The broadly affirmative findings of these exercises may
be compared with similar appraisals of dobutamine and PDE
inhibitors, which have been associated with overall worse
mid-to-long-term prognosis.78–80 These contrasting findings
highlight the distinction between inotropes that act, via either
adrenergic or PDE-targeted pathways, to increase intracellular
cAMP levels in cardiomyocytes and levosimendan, realizing
the ambitions of its inventors by promoting cardiac contrac-
tility without compromising the longer-term viability of car-
diac muscle cells. This distinction is also illuminated by
findings from the Acute Heart Failure Global Survey of
Standard Treatment (ALARM-HF) registry, data from which
were strongly indicative of survival benefit from levosimen-
dan vis-à-vis adrenergic/calcium-mobilizing inotropes, such
as dobutamine.81
LEVOSIMENDAN IN CURRENT USE
The nonunivocal findings of long-term survival benefit
from short-term treatment with IV levosimendan have not
prevented the drug from establishing itself in the therapeutic
repertoire: it has been used in almost 2 million patients since
2000, when its first market authorization was granted by the
Swedish regulatory authorities on the basis of the data
available at that time.
Its favorable, rapid, and sustained impact on hemody-
namics, neurohormone levels, and symptoms in acute decom-
pensated HF are undisputed and of clear therapeutic value.
Formal acknowledgement of that value emerged in 2005,
when it was mandated in the ESC guidelines.82 In the sub-
sequent European guidelines (2008, 2012), the endorsements
of levosimendan were more cautious, reflecting a general dis-
satisfaction of the HF medical community with the concept of
inotropy.83,84 Levosimendan is currently recommended in the
acute treatment of HF to reverse the effect of beta-blockade, if
beta-blockade is thought to be contributing to hypotension
with subsequent hypoperfusion.85
Due to the large therapeutic field they encompass, the
European guidelines on acute and chronic HF are not as
detailed as they could be and, in recommending therapeutic
agents, ignore some of the different etiologies and manifes-
tations of AHF. Supplemental Digital Content 1 (see
Supplementary Information, http://links.lww.com/JCVP/
A472) and recommendations can be found in more than 20
expert consensus papers coauthored by more than 180 clini-
cians from 30 countries who have discussed when and how to
use levosimendan in different therapeutic settings, including
AHF and cardiogenic shock,74,81,86–88 AdHF,89–92 periopera-
tive use,93–95 and use in the intensive care unit (ICU),96 and
who have described its cardiorenal effects,88,97 its effects on
quality of life,98,99 exercise performance,100 lung function,101
and pharmacoeconomic considerations.102
In the context of a 20-year retrospective, it is worth
noting at this point that its complex mode of action might
have had the potential to disadvantage levosimendan both in
fact and in perception. In fact, that plurality of effects has
emerged as both an important aspect of the drug’s clinical
versatility and usefulness and as a stimulant to informed spec-
ulation among experts and to medical research.73,92,94,96,103
Levosimendan in Acute Settings
The most recent ESC guidelines, issued in 2016,
identify short-term treatment with IV levosimendan (along
with adrenergic inotropes or PDE inhibitors) as an option in
the acute-phase management of “patients with hypotension
(SBP ,90 mmHg) and/or symptoms of hypoperfusion
despite adequate filling status, to increase CO, increase blood
pressure, improve peripheral perfusion and maintain end-
organ function.”85 The ESC statement further endorses the
short-term use of levosimendan to circumvent the effects of
beta-blockade “if beta-blockade is thought to be contributing
to hypotension with subsequent hypoperfusion.” The high
proportion of patients now receiving beta-blockers as part
of the treatment repertoire for chronic HF means that levosi-
mendan has become an important resource in the manage-
ment of acute decompensations in those patients.
The vasodilator dimension of levosimendan’s pharma-
cology is pertinent to the drug’s use in low-output states such
as AHF, in which a key pathology is organ hypoperfusion. A
drug that both augments CO and improves vasodilatation may
FIGURE 6. Results of 64 meta-analyses of levosimendan clinical trials. Refer to the supplementary material for details of the
individual meta-analyses.
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be expected to have a more favorable impact in some cases
than an agent that acts on CO alone.104
In this context, it is important to register that, in many
acute settings, hypoperfusion and hypotension may not
necessarily be only an effect of inadequate myocardial
contractility but may also be related to shock-specific changes
in vascular tone and vasodilatation. Thus, besides the need to
exclude or correct inadequate volume status, concomitant
treatment with a vasopressor agent before embarking on
a course of inotropic therapy must also be considered. The
importance of correcting inadequate volume before embark-
ing on a course of vasodilatory or inotropic therapy must also
be considered and monitored during therapy. These observa-
tions may be usefully contextualized into a ‘right patient,
right drug’ schema that can be used to guide vasoactive
and/or inotropic therapy (Table 3).105 The first phase of this
schema examines whether or not an inotrope is needed at all
and includes exclusion of otherwise treatable causes or the
availability of viable alternatives. The next step is to identify
the most suitable inotrope: levosimendan figures prominently
in several categories, including cardiogenic shock, cardiac
surgery, and right ventricular failure.
Cardiogenic Shock
The purpose of inotropic support in cardiogenic shock
secondary to left ventricular dysfunction is to aid the failing
left ventricle by unloading it, increasing left ventricular
output, and improving coronary blood flow and hence
myocardial perfusion, at the same time decreasing pulmonary
edema. The inodilator profile of levosimendan provides
a possibly more complete response to those needs than pure
inotropic agents, and its ability to promote inotropy with little
or no adverse effect on metabolic rate, energy demand, or
oxygen consumption may be a bonus. Use of levosimendan
may be beneficial in part via a substitution effect in which it
reduces the need for catecholaminergic agents, which have
less favorable effects on oxygen and energy consumption at
the cellular level and a propensity to increase mortality.106
Formal experience with levosimendan in cardiogenic
shock is limited, but it appears to be generally well tolerated,
to improve multiple indices of cardiac function, and to reduce
systemic vascular resistance.106–111 Levosimendan has also
been reported to restore ventriculoarterial coupling and
improve left ventricular function in various settings: this
may be a further benefit in cardiogenic shock, but this con-
jecture is currently untested.112,113
Takotsubo Syndrome
An example of cardiogenic shock in which treatment
with levosimendan presents unique benefits is takotsubo
syndrome, or stress cardiomyopathy.114 Takotsubo-induced
HF and/or cardiogenic shock is commonly treated with
aggressive diuresis, hemodynamic support, and inotropic
drugs. The fact that catecholamines may be implicated in its
pathogenesis suggests that catecholamine inotropes may be
contraindicated, because these drugs increase cAMP within
the cell, increase myocardial oxygen consumption, and may
worsen myocardial stunning. Levosimendan, by contrast, as
a noncatecholamine inotrope that does not increase myocyte
cAMP or oxygen consumption, is a rational therapeutic
option in Takotsubo-related cardiogenic shock.115–117
Cardiac Surgery
Levosimendan has been studied in more than 40 clinical
trials in cardiac surgery, with indications emerging that it can
reduce the risk of low cardiac output syndrome (LCOS) or be
effective in treating postoperative LCOS. The scale of this
benefit (derived from a meta-analysis of 14 studies) is
moderate but tangible, and is more marked in patients with
baseline low left ventricular ejection fraction.118
A recalculation incorporating data from 3 recent large
RCTs [Levosimendan in Coronary Artery Revascularisation
(LICORN), Levosimendan to Reduce Mortality in High Risk
Cardiac Surgery Patients (CHEETAH), and LEVO-CTS]
causes dilution of the effect size of that estimate.119–122
Expert advice derived from these new data is that “levosi-
mendan cannot be at the moment recommended for routine
use in all cardiac surgery settings.”122 However, there appears
to be potential for significant mortality benefit in some sub-
groups of patients, such as those with low ejection fraction or
those undergoing isolated coronary artery bypass grafting
(CABG) procedures.123,124 Whether these findings may be
interpreted as a lack of efficacy of levosimendan in patients
undergoing valve surgery due to differences in the underlying
pathophysiology or dosing, or as a result of procedure-
specific differences in surgical and perfusion management
(ie, too low a dose applied before cardiopulmonary bypass
or use of crystalloid cardioplegia solutions) needs to be ad-
dressed in future studies.
TABLE 3. Common Concomitant Conditions in Acute HF and
the Corresponding Inotrope of Choice
Commonly Encountered
Concomitant Conditions in Acute
HF Inotrope of Choice
Hypotension Norepinephrine
Dobutamine
Dopamine
Beta-blockade Levosimendan
Milrinone
Pulmonary hypertension Levosimendan
Milrinone
Acute cardiorenal syndrome Dopamine
Levosimendan
Dobutamine
HF of ischemic etiology Levosimendan
Dobutamine
Cardiopulmonary bypass surgery Dobutamine
Levosimendan
Milrinone
Sepsis-related HF Norepinephrine
Dobutamine
Levosimendan
Source: Bistola et al105 Reproduced with permission from Radcliffe Cardiology.
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The emphasis on postoperative mortality in these recent
studies was substantially driven by regulatory requirements in
the design of LEVO-CTS. Whether that outcome is the most
relevant or revealing for evaluation of an intervention is an
open question. Levosimendan exhibited efficacy in other
measures, including a lower incidence of LCOS, less need for
rescue catecholamines for inotropic support, and augmenta-
tion of the cardiac index.118 Methodological difficulties also
affected the interpretation of the LICORN and CHEETAH
trials.
These caveats notwithstanding, mortality was numeri-
cally lower in levosimendan-treated patients in LEVO-
CTS.118 In addition, the safety profile of levosimendan re-
vealed in all these recent trials identifies it as arguably the
safest agent among the broad grouping of inotropes and in-
odilators. There was no significant excess of arrhythmias or
hypotension and no increase in mortality in levosimendan-
treated patients.118
Encouragement for further evaluation of levosimendan
in this area comes from other recent investigations. Wang
et al123 analyzed data from 21 randomized trials (n = 1727)
and calculated that IV levosimendan in patients undergoing
CABG was associated with significant reductions in mortality
rate (P = 0.001) and postoperative atrial fibrillation (P =
0.04), with benefit mostly restricted to patients pretreated in
advance of an isolated CABG procedure; on-pump status also
affected outcomes.123 Levosimendan was associated with
a higher incidence of hypotension (OR 2.26). These data
are consistent with the findings from LEVO-CTS and offer
indications of future lines of clinical appraisal.118,124 See also
Weber et al.125
Right Ventricular Failure
Determinative randomized trials of levosimendan in
right ventricular failure (with or without pulmonary hyper-
tension) have yet to be conducted but a recent meta-analysis
of 10 studies of levosimendan in acute right-sided HF
identified statistically robust benefits over placebo, with
increases in tricuspid annular plane systolic excursion and
ejection fraction, plus reductions in systolic pulmonary artery
pressure (P = 0.0001) and pulmonary vascular resistance (P =
0.003).126 Adverse events were reported not to differ signif-
icantly between groups.
Effects on Renal Function in HF and Critical
Illness
HF is a systemic syndrome involving the kidneys,
lungs, and liver, with a great impact on prognosis, and effects
of cardiovascular drugs on noncardiac organs are of the
utmost importance.127 Evidence for a renal-protective action
of levosimendan has been reported from preclinical experi-
ments.128–130 It has been proposed that levosimendan may
cause selective vasodilation on the afferent arterioles of the
renal glomeruli, thus improving renal filtration.97 This sug-
gestion is compatible with findings from the LIDO trial, in
which levosimendan treatment was associated with an
increase in the estimated glomerular filtration rate (eGFR)
but treatment with dobutamine was not, even though both
drugs increased cardiac index and urine output.63 It is also
consistent with recent reports by Fedele et al131 and by
Lannemyr et al.132 The substantial enhancement of the
eGFR observed in the second of those studies was not accom-
panied by impairment of renal oxygenation, given that renal
oxygen delivery increased in proportion to the increase in the
eGFR. Nonimpairment of the renal oxygen supply–demand
relationship despite eGFR enhancement during levosimendan
exposure has also been reported by Bragadottir et al.133 A
recent report shows that the eGFR enhancement effect of
levosimendan is not shared with milrinone.134
Data on the effects of levosimendan on renal function in
various clinical situations, including cardiac surgery and
critical illness, have been collated and the results support
a renal-protective effect, making levosimendan the inotrope
of choice in the case of worsening cardiorenal syndrome.135–
138 However, in all these situations, specifically designed pro-
spective trials of adequate statistical power will be needed to
confirm the effects and their clinical consequences.
Levosimendan in AdHF
Adoption of repeated intermittent cycles of IV levosi-
mendan for the treatment of AdHF has been a significant
milestone in both the lifecycle of the drug and the manage-
ment of a complex aspect of HF. Patients with AdHF are on
a trajectory ultimately either to a definitive intervention
through heart transplantation or the implantation of a left
ventricular assist device (LVAD), or to a palliative care
pathway. Goals of therapy in AdHF include hemodynamic
stabilization and preservation of functional capacity, mitiga-
tion of symptoms, and preservation of health-related quality
of life. Prevention of HF-related hospitalization is another key
goal, both as a desirable outcome per se and as a way of
averting the markedly worsened mortality that accompanies
hospitalization.139,140
All of the pharmacological properties of levosimendan
outlined earlier—notably its metabolite-mediated persistence
of effect—make it well-suited for repeated or intermittent use
in the management of AdHF.
Three randomized, placebo-controlled, double-blind
clinical trials, Randomised Trial Investigating the Efficacy
and Safety of Pulsed Infusions of Levosimendan in
Outpatients with Advanced Heart Failure (Levo-Rep;
NCT01065194), Levosimendan Intermittent Administration
in Outpatients: Effects on Natriuretic Peptides in Advanced
Chronic Heart Failure (LION-HEART; NCT01536132), and
Long-Term Intermittent Administration of Levosimendan in
Patients with Advanced Heart Failure (LAICA;
NCT00988806), have examined the application of repeated
cycles of levosimendan therapy in this setting.141–143 All
these studies demonstrated that repeat-cycle levosimendan
reduces N-terminal pro-BNP (NT-proBNP) levels, and there
were repeated and clear demonstrations of trends toward re-
ductions in HF readmissions and mortality that are consistent
with, and corroborate, the findings of meta-analyses.144,145 A
recognized overall conclusion from these studies is that repet-
itive application of levosimendan is feasible and safe in an
outpatient setting.141–143 Notably, onset destabilization is not
invariably an immediate-onset event, however, and it may be
possible to identify opportunities when timely recognition of
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—and intervention on—signs and symptoms of decompensa-
tion may avoid unplanned/urgent hospitalizations due to
hemodynamic crises.
The need for a larger randomized study (or studies) in
this area is being addressed by the Repetitive Levosimendan
Infusion for Patients with Advanced Chronic Heart Failure
trial (LEODOR; NCT03437226), a multicenter, randomized,
double-blind, placebo-controlled, 3-arm trial, which will
examine the impact and safety of intermittent levosimendan
therapy, started during the vulnerable phase after a recent
hospitalization for HF.146 Treatment effectiveness will be as-
sessed using a hierarchical composite clinical end point con-
sisting of time to death or urgent heart transplantation or
implantation of a ventricular assist device; time to nonfatal
HF hospitalization requiring IV vasoactive therapy; and time-
averaged proportional change in NT-proBNP. Basing the trial
on such an outcome measure should enhance the power to
examine whether, compared with placebo, repeated use of
levosimendan is associated with greater clinical stability over
the course of subsequent weeks.
In addition to its use in maintaining hemodynamic
stability in patients with AdHF, preoperative use of IV
levosimendan in patients undergoing implantation of an
LVAD, or identification of LVAD candidates, has been
reported to be “generally well-tolerated and not interrupted
because of side effects” and associated with significant im-
provements in end-organ function, although with similar early
mortality rates.147 This is an application where a substantial
expansion in the use of levosimendan may be anticipated.
The current clinical applications of IV levosimendan
are summarized in Table 4.
THE NEXT 20 YEARS OF LEVOSIMENDAN
In addition to the LEODOR study, there are currently
more than 20 investigator-initiated clinical trials in progress in
which levosimendan is being evaluated for possible thera-
peutic benefits. These include: a study designed to examine
the effect of a single 24-hour infusion of levosimendan to
prevent rehospitalization in patients with severe systolic HF
(NCT03764722); Effect of Levosimendan or Placebo on
Exercise in Advanced Chronic Heart Failure (LOCO-CHF;
NCT03576677), a placebo-controlled appraisal of the effects
of IV levosimendan on exercise capacity in patients with
advanced chronic HF; and research into the effects of
levosimendan on acute kidney injury after cardiac surgery
(LEVOAKI; NCT02531724). The Early Management
Strategies of Acute Heart Failure for Patients with NSTEMI
study (EMSAHF; NCT03189901) is exploring whether early
use of levosimendan in patients with acute MI combined with
elevated BNP/NT-proBNP may reduce the risk of emergent
AHF and improve outcome.
Developments in the technology and science of
telemedicine and telemonitoring may make this a practical
proposition in the foreseeable future. The ambition (already
under active exploration and with progress further accel-
erated by the introduction of artificial intelligence into the
diagnostic loop) is to develop patient monitoring to such
a degree of immediacy and accuracy that overt decom-
pensations may be wholly avoided by prompt, appropriate
clinical responses to the first signs of deterioration.148,149
Intermittent IV levosimendan may be an appropriate inter-
vention in this ‘acute but nonhospitalized’ scenario, de-
pending on the clinical circumstances of an individual
patient. Investigations in this direction can be expected,
although these are likely to be driven primarily by develop-
ments in telemedicine technologies, rather than by any
focus on specific medical interventions.150
A range of ICU situations has been identified in which
levosimendan may offer clinical benefits, either as an adjunct
to existing interventions or as an alternative to conventional
therapies. These situations include: hemodynamic support in
cardiac critical care,151 hemodynamic support in septic car-
diomyopathy,152,153 weaning from the ventilator,154 weaning
from venoarterial extracorporeal membrane oxygenation after
cardiac surgery,155–159 and renal failure and kidney protection
in cardiorenal syndrome.97,130,132,160–166
In several of these areas, notably low CO syndrome,
cardiogenic shock, Takotsubo cardiomyopathy, and sep-
sis, a substantial element of any benefit accruing from use
of levosimendan may be attributable to the substitution of
a nonadrenergic stimulant for conventional catecholamin-
TABLE 4. Current Clinical Applications of IV Levosimendan
Indications Described Clinical Benefits
Settings Symptoms Hemodynamics Neurohormones End-Organ Function Rehospitalization Survival
Acute HF Y [ Y [ Y 4[
Cardiogenic shock n.d. [ n.d. 4 n.d. 4
Takotsubo syndrome Y [ Y [ n.d. n.d.
RV failure Y [ n.d. [ n.d. 4
HF after ACS Y [ n.d. n.d. n.d. 4
Cardiac surgery n.d. [ Y [ n.d. 4[
LCOS after CABG n.d. [ n.d. [ n.d. [
Septic shock n.d. [ 4 4 n.d. 4
Advanced HF Y [ Y [ Y [
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; HF = heart failure; LCOS = low-output cardiac syndrome; n.d. = not described RV = right ventricular.
Levosimendan Efficacy and SafetyJ Cardiovasc Pharmacol  Volume 76, Number 1, July 2020
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. www.jcvp.org | 15
ergic agents, such as dobutamine, thereby averting some
of the potential toxic complications of adrenergic
overstimulation.167
‘Decatecholaminization’ of the medical armamentarium
is a developing line of practice in the management of criti-
cally ill patients.168–176 As an established nonadrenergic vaso-
active agent that offers positive cardiovascular effects (eg,
ventriculoarterial recoupling, decongestion), as well as poten-
tially advantageous ancillary effects on kidney function and
cellular-protective actions, levosimendan is both a therapeutic
resource and experimental tool for investigating this new
approach.161,177–184
Developments in these areas, although already pioneered
by promising exploratory studies, will, inevitably, require well-
designed and properly powered RCTs.151–153,185,186
Central to future investigations will be the identification
of robust and relevant end points. An overemphasis on crude
mortality may not be the most informative metric by which to
judge outcomes. Trials directed toward establishing the best
overall therapeutic strategy may be more progressive than
studies framed to position any one agent as the best for
a particular purpose or situation. Various commentaries have
examined the challenges of conducting clinical trials in
critically ill patients.187–190 Of notable significance in this
respect is the work of Mebazaa et al,191 who have sought to
apply lessons learned from trials in AHF to the more flexible
and less prescriptive design of phase III studies in sepsis.
Principal among those lessons is the need to move toward
composite primary end points, with isolated all-cause mortality
addressed as a safety signal, not a primary marker of
effectiveness. From that perspective, the model of HF as
a complex condition of multifactorial causes and pathophysiol-
ogy, and one therefore unlikely to be moderated by a single
intervention on a simple outcome measure such as total
mortality, is an example of a needlessly restrictive approach to
clinical trials design that has had a dampening effect on the
development of needed therapies. In addition, there has been
recent discussion about how syndrome-attributable risks of
critical illness-associated diagnoses have often likely been
overestimated using common statistical methods, contributing to
very low success rates in this field.192 The authors of this article
are unanimously supportive of that view, which we feel has
frustrated advances in HF care. It is to be hoped that our col-
leagues in cardiac critical care are able to benefit in the design of
their own clinical trials by examining some of the methodo-
logical missteps and misplaced emphases that have hampered
some aspects of cardiology research in recent decades.
Levosimendan has been approved by Chinese author-
ities on the basis of several local corroborative regulatory
clinical trials, and SIMDAX will enter that important market
this year.161,193–195
The use of levosimendan in pediatric patients is currently
contraindicated due to a lack of regulatory studies. A few
investigator-initiated studies have been performed. The largest
published study included retrospectively gathered data on 484
levosimendan infusions delivered to 293 patients at a single
pediatric ICU; the majority of the patients (65%) were aged
12 months or younger.196 Levosimendan postponed or reduced
the need for mechanical cardiac support in children with
cardiomyopathy or who were undergoing cardiac surgery. In
other reports, levosimendan was compared to the PDE inhibitor
milrinone and found to be either similarly efficacious or supe-
rior.197–199 In a randomized double-blind study in children
younger than 4 years of age undergoing cardiac surgery, pa-
tients receiving levosimendan had significantly higher cardiac
index and lower pulmonary artery pressure than children
receiving dobutamine.200 There is a strong rationale to perform
properly powered clinical regulatory trials on the pediatric use
of levosimendan in the near future.
Research and Development Outside
Cardiology
Respiratory Function
Respiratory muscle dysfunction may develop in the
course of several diseases, including chronic obstructive
pulmonary disease, HF, and critical illness.201,202 In addition
to atrophy, reduced calcium sensitivity of contraction plays an
important role in respiratory muscle weakness in these con-
ditions.203,204 Levosimendan has been studied in noncardiac
muscle, especially in respiratory muscles. In vitro studies
have demonstrated that levosimendan improves calcium sen-
sitivity of force generation in diaphragm fibers from healthy
subjects and patients with chronic obstructive pulmonary dis-
ease.203 In a physiological study, levosimendan at a clinically
used dose improved diaphragm contractile efficiency by 21%
and reversed diaphragm fatigue induced by inspiratory mus-
cle loading.205 In a placebo-controlled randomized study, the
effects of levosimendan were evaluated in critically ill pa-
tients being weaned from mechanical ventilation.206 There
was no difference in the primary end point of contractile
efficiency between groups, although tidal volume and minute
ventilation were both significantly higher in the levosimendan
group, and arterial CO2 tension significantly lower.206
Improved respiratory mechanics may facilitate liberation from
mechanical ventilation, although this requires further clinical
studies.
Pulmonary Hypertension
A phase II regulatory clinical trial is currently underway
in the United States on the repeated use of IV levosimendan
for pulmonary hypertension in patients with HF and pre-
served ejection fraction (NCT03541603). The results are
expected in 2020.
Motor Neuron Disease
There is interest in the potential of oral levosimendan in
the management of amyotrophic lateral sclerosis (ALS). ALS
is characterized by a progressive muscular paralysis arising
from motor neuron degeneration.207 The disease eventually
involves most skeletal muscles, plus the diaphragm and other
respiratory muscles, leading to death from respiratory fail-
ure.208,209 It is the most common neurodegenerative disorder
of mid-life, with incidence and prevalence increasing with
age.210 ALS is currently incurable, and the medical options
are limited. No treatment is currently approved to enhance
motor function in ALS, and recent clinical experiences have
produced mixed results.211–214
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The physiological and pharmacological rationale for
levosimendan in ALS rests on the fact that both the
diaphragm and skeletal muscle express genes for the slow-
twitch (or cardiac) isoform of TnC (the diaphragm consists of
approximately 50% slow-twitch fibers).215 As a calcium sen-
sitizer with cTnC as molecular target, levosimendan can thus
strengthen contractility also in the diaphragm and skeletal
muscle. The multifaceted pharmacology of levosimendan
may also provide supplementary clinical impact in patients
with ALS through the already-mentioned range of pharmaco-
logical effects not directly related to the drug’s calcium-
sensitizing action.37,216
Positive effects of short-term oral levosimendan in
patients with ALS were seen in the Effects of ODM-109 on
Respiratory Function in Patients With ALS (LEVALS;
NCT02487407) study, a phase II trial that used a randomized,
double-blind, placebo-controlled, cross-over design to evalu-
ate the efficacy and safety of oral levosimendan in patients
with definite or probable ALS. The 66 patients enrolled had
experienced symptoms of ALS for between 12 and 48 months
and had an early decline in respiratory function. Therapy
consisted of 2 weeks of oral levosimendan at doses of 1 or 2
mg/d or placebo, administered in random order during 3 study
periods separated by a wash-out period.217
The phase III Effects of Oral Levosimendan (ODM-
109) on Respiratory Function in Patients with ALS trial
(REFALS; NCT03505021) is ongoing in North America,
Europe, and Australia. An open-extension phase of REFALS
should offer important insights into the long-term safety and
efficacy of oral levosimendan in ALS.
Translational and Early Development Phases
Other trials are looking at the effects of IV levosimen-
dan on cellular metabolic alterations in patients with septic
shock (NCT02963454) and the possibility that IV levosi-
mendan may improve the prognosis in acute respiratory
distress syndrome (NCT04020003).
Other recent research on the effect of levosimendan on
oxidative stress in a mouse model of diabetes showing an
effect of the drug in preventing memory impairment has
opened up a new possible development path.218,219 A separate
report, again in mice, highlighted the protective effects eli-
cited by levosimendan against liver ischemia/reperfusion
injury.220
Of particular interest, new pharmaceutical agents are
currently being developed with levosimendan and cTnC as
a pharmacophore model in unexpected fields such as
oncology.221
CONCLUSIONS
In the field of short-term hemodynamic treatments for
acute cardiac care, levosimendan represents a rare case of an
inotrope approved by regulatory authorities in the past
20 years. The approval was based on data from 3 phase III
clinical studies in which the end points were reached (LIDO,
RUSSLAN, and REVIVE).62,63,65 The safety data collected
during those 20 years of clinical use are unprecedented and
superior to those for any of the other inotropes or
inodilators.222 In a recent consensus paper, the authors eval-
uated whether “the nearly total absence of evidence of benefit
with some of the traditional IV drugs used in AHF and AdHF
(such as the catecholamines or the PDE inhibitors) would
warrant their elimination from routine use in favor of treat-
ments where such evidence has been accrued (e.g. for levo-
simendan).”75 With regard to posology, both a frequent use in
the therapy of AdHF and an earlier use of levosimendan in the
therapy of AHF have been shown to be of benefit.91,223
Beyond that, 20 years after its initial approval for clinical
use, levosimendan remains an important resource in cardio-
vascular medicine and a valuable tool for clinical research,
investigation, and innovation in that and other areas of med-
icine.20 The clinical program for the development of oral
levosimendan as a treatment for ALS shows how retargeting
a safe drug, even in a different formulation, is a rational strat-
egy in pharmaceutical development.224
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